يعرض 21 - 40 نتائج من 29,547 نتيجة بحث عن '(( significant ((changes decrease) OR (largest decrease)) ) OR ( significantly reduced ejection ))', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 21

    Decadal mean regional hydrology. حسب Nic Gedney (19762301)

    منشور في 2024
    الموضوعات:
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30

    Species1 from Tropical mammal functional diversity increases with productivity but decreases with anthropogenic disturbance حسب Daniel Gorczynski (10093617)

    منشور في 2021
    "…Mammal community functional dispersion increased with primary productivity, while functional richness decreased with human-induced local extinctions and was significantly lower in Madagascar than other tropical regions. …"
  11. 31
  12. 32
  13. 33
  14. 34

    Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction حسب Hannah A. Blair (6846307)

    منشور في 2021
    "…<br></p><p><br></p><p></p><p><b>Abstract </b>Dapagliflozin [Farxiga<sup>®</sup> (USA); Forxiga<sup>® </sup>(EU)], a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults with symptomatic heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI 58 trial, in which dapagliflozin 10 mg/day significantly reduced the risk of CV death or hospitalization for HF in patients with type 2 diabetes mellitus (T2DM) who had or were at risk for atherosclerotic CV disease. …"
  15. 35

    Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction حسب Connie Kang (7248215)

    منشور في 2022
    "…<br> </p> <p><br></p> <p>Abstract</p> <p>Vericiguat (Verquvo<sup>®</sup>) is the first oral soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of adults with symptomatic, chronic heart failure with reduced ejection fraction (HFrEF). In the phase III VICTORIA trial, vericiguat added to standard of care (SOC) was associated with a significantly lower risk of the primary composite endpoint of death from cardiovascular (CV) causes or first hospitalization from heart failure (HHF) than placebo added to SOC in adults with chronic HFrEF. …"
  16. 36

    Cost-of-illness of heart failure with preserved and reduced ejection fraction in the Philippines حسب John Añonuevo (20494293)

    منشور في 2025
    "…</p> <p>The study utilized a bottom-up micro-costing approach to determine the economic burden of heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) across all NYHA classifications using a societal perspective. …"
  17. 37
  18. 38
  19. 39
  20. 40